1. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center;Afzal;Melanoma Res.,2018
2. Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice;Ahern;Clin. Cancer Res.,2017
3. Epigenetic modifiers as new immunomodulatory therapies in solid tumors;Aspelagh;Ann. Oncol.,2018
4. Cancer prevention and therapy through the modulation of the tumor microenvironment;Casey;Sem. Cancer Biol.,2015
5. The role of RANK-ligand inhibition in cancer: the story of denosumab;Castellano;Oncologist,2011